JPWO2020010068A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020010068A5 JPWO2020010068A5 JP2020572517A JP2020572517A JPWO2020010068A5 JP WO2020010068 A5 JPWO2020010068 A5 JP WO2020010068A5 JP 2020572517 A JP2020572517 A JP 2020572517A JP 2020572517 A JP2020572517 A JP 2020572517A JP WO2020010068 A5 JPWO2020010068 A5 JP WO2020010068A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline salt
- pharmaceutical composition
- salt according
- subject
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076310A JP2024105460A (ja) | 2018-07-02 | 2024-05-09 | ２－（３，５－ジクロロ－４－（（５－イソプロピル－６－オキソ－１，６－ジヒドロピリダジン－３－イル）オキシ）フェニル）－３，５－ジオキソ－２，３，４，５－テトラヒドロ－１，２，４－トリアジン－６－カルボニトリルの固体形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692914P | 2018-07-02 | 2018-07-02 | |
| US62/692,914 | 2018-07-02 | ||
| PCT/US2019/040276 WO2020010068A1 (en) | 2018-07-02 | 2019-07-02 | Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076310A Division JP2024105460A (ja) | 2018-07-02 | 2024-05-09 | ２－（３，５－ジクロロ－４－（（５－イソプロピル－６－オキソ－１，６－ジヒドロピリダジン－３－イル）オキシ）フェニル）－３，５－ジオキソ－２，３，４，５－テトラヒドロ－１，２，４－トリアジン－６－カルボニトリルの固体形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530456A JP2021530456A (ja) | 2021-11-11 |
| JP2021530456A5 JP2021530456A5 (https=) | 2022-07-08 |
| JPWO2020010068A5 true JPWO2020010068A5 (https=) | 2022-07-08 |
Family
ID=67441642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572517A Pending JP2021530456A (ja) | 2018-07-02 | 2019-07-02 | ２−（３，５−ジクロロ−４−（（５−イソプロピル−６−オキソ−１，６−ジヒドロピリダジン−３−イル）オキシ）フェニル）−３，５−ジオキソ−２，３，４，５−テトラヒドロ−１，２，４−トリアジン−６−カルボニトリルの固体形態 |
| JP2024076310A Pending JP2024105460A (ja) | 2018-07-02 | 2024-05-09 | ２－（３，５－ジクロロ－４－（（５－イソプロピル－６－オキソ－１，６－ジヒドロピリダジン－３－イル）オキシ）フェニル）－３，５－ジオキソ－２，３，４，５－テトラヒドロ－１，２，４－トリアジン－６－カルボニトリルの固体形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076310A Pending JP2024105460A (ja) | 2018-07-02 | 2024-05-09 | ２－（３，５－ジクロロ－４－（（５－イソプロピル－６－オキソ－１，６－ジヒドロピリダジン－３－イル）オキシ）フェニル）－３，５－ジオキソ－２，３，４，５－テトラヒドロ－１，２，４－トリアジン－６－カルボニトリルの固体形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210122740A1 (https=) |
| EP (2) | EP3818057A1 (https=) |
| JP (2) | JP2021530456A (https=) |
| KR (2) | KR102890565B1 (https=) |
| CN (1) | CN112638904A (https=) |
| AR (1) | AR115666A1 (https=) |
| AU (2) | AU2019298236A1 (https=) |
| CA (1) | CA3104860A1 (https=) |
| IL (2) | IL321116A (https=) |
| MX (3) | MX2021000107A (https=) |
| TW (1) | TW202019914A (https=) |
| WO (1) | WO2020010068A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT4406594T (lt) | 2012-09-17 | 2025-12-29 | Madrigal Pharmaceuticals, Inc. | Skydliaukės hormono analogai |
| IL266054B2 (en) | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
| US12338206B2 (en) | 2019-02-21 | 2025-06-24 | Nanjing Ruijie Pharma Co., Ltd. | Compounds and their uses as thyroid hormone receptor agonists |
| GEP20247637B (en) | 2019-05-08 | 2024-06-25 | Aligos Therapeutics Inc | Modulators of thr-b and methods of use thereof |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| WO2021129465A1 (zh) * | 2019-12-26 | 2021-07-01 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| US12595254B2 (en) | 2020-09-10 | 2026-04-07 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of Resmetirom, preparation method therefor, and use thereof |
| WO2022086894A1 (en) | 2020-10-19 | 2022-04-28 | Teva Pharmaceuticals International Gmbh | Solid state forms of resmetirom |
| KR20230142523A (ko) * | 2021-02-01 | 2023-10-11 | 마드리갈 파마슈티칼스, 인크. | 간 장애 또는 지질 장애의 치료를 위한 로수바스타틴 및 레스메티롬의 치료용 조합 |
| CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
| WO2022225827A1 (en) * | 2021-04-21 | 2022-10-27 | Merck Sharp & Dohme Llc | Novel forms of cyclic dinucleotide compounds |
| JP2024544538A (ja) * | 2021-11-11 | 2024-12-03 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | ＴＨＲ－βアゴニストによる肝障害の治療 |
| WO2024263714A1 (en) | 2023-06-22 | 2024-12-26 | Madrigal Pharmaceuticals, Inc. | BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-β AGONISTS AND RELATED USES |
| WO2025011259A1 (zh) * | 2023-07-07 | 2025-01-16 | 苏州科睿思制药有限公司 | 瑞司美替罗的晶型及其制备方法和用途 |
| CN119613386A (zh) * | 2023-09-14 | 2025-03-14 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法 |
| WO2025083699A2 (en) | 2023-10-16 | 2025-04-24 | Cipla Limited | Resmetirom polymorphs and process thereof |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025171032A1 (en) | 2024-02-06 | 2025-08-14 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025172958A1 (en) * | 2024-02-16 | 2025-08-21 | Metrochem Api Pvt Ltd | Solid state forms of resmetirom |
| WO2025231587A1 (zh) * | 2024-05-06 | 2025-11-13 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗无水晶型ch及其制备方法 |
| WO2026067708A1 (zh) * | 2024-09-30 | 2026-04-02 | 齐鲁制药有限公司 | 瑞司美替罗晶型及其制备方法和用途 |
| WO2026074443A1 (en) | 2024-10-01 | 2026-04-09 | Assia Chemical Industries Ltd. | Solid state forms of resmetirom |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001051919A2 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| PL1919878T3 (pl) * | 2005-07-21 | 2011-03-31 | Hoffmann La Roche | Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy |
| LT4406594T (lt) * | 2012-09-17 | 2025-12-29 | Madrigal Pharmaceuticals, Inc. | Skydliaukės hormono analogai |
| IL266054B2 (en) * | 2016-10-18 | 2023-10-01 | Madrigal Pharmaceuticals Inc | Methods for treating liver disorders or lipid disorders using a THR-BETA agonist |
-
2019
- 2019-07-01 TW TW108123112A patent/TW202019914A/zh unknown
- 2019-07-01 AR ARP190101846A patent/AR115666A1/es unknown
- 2019-07-02 CA CA3104860A patent/CA3104860A1/en active Pending
- 2019-07-02 JP JP2020572517A patent/JP2021530456A/ja active Pending
- 2019-07-02 IL IL321116A patent/IL321116A/en unknown
- 2019-07-02 WO PCT/US2019/040276 patent/WO2020010068A1/en not_active Ceased
- 2019-07-02 KR KR1020217003360A patent/KR102890565B1/ko active Active
- 2019-07-02 EP EP19745399.6A patent/EP3818057A1/en not_active Withdrawn
- 2019-07-02 KR KR1020257038532A patent/KR20250167140A/ko active Pending
- 2019-07-02 EP EP24214548.0A patent/EP4552643A3/en active Pending
- 2019-07-02 US US17/257,070 patent/US20210122740A1/en not_active Abandoned
- 2019-07-02 CN CN201980056826.0A patent/CN112638904A/zh active Pending
- 2019-07-02 AU AU2019298236A patent/AU2019298236A1/en not_active Abandoned
- 2019-07-02 MX MX2021000107A patent/MX2021000107A/es unknown
-
2020
- 2020-12-23 IL IL279700A patent/IL279700A/en unknown
-
2021
- 2021-01-06 MX MX2024013198A patent/MX2024013198A/es unknown
- 2021-01-06 MX MX2023009701A patent/MX2023009701A/es unknown
-
2024
- 2024-05-09 JP JP2024076310A patent/JP2024105460A/ja active Pending
- 2024-11-15 US US18/949,309 patent/US20250074898A1/en active Pending
-
2025
- 2025-01-10 AU AU2025200189A patent/AU2025200189A1/en active Pending
- 2025-08-19 US US19/303,585 patent/US20250368626A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530456A5 (https=) | ||
| JPWO2020010068A5 (https=) | ||
| US20250074898A1 (en) | Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile | |
| JP2021183628A (ja) | カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法 | |
| JP2008521829A5 (https=) | ||
| TW201121544A (en) | Novel phenol derivative | |
| JP2020519654A5 (https=) | ||
| CN108601751A (zh) | 雷公藤红素的类似物 | |
| TW201043601A (en) | Substituted aromatic compounds and pharmaceutical uses thereof | |
| JP4927098B2 (ja) | トリアルキルシリルベンジルアミノカルボキシインドール、インダゾールおよびインドリン、ならびにｃｅｔｐを介する障害の処置におけるそれらの使用 | |
| CN103228618B (zh) | 新化合物及其医药用途 | |
| TW200815319A (en) | Aminoalcohol derivative and immunosuppressant containing the same as active ingredient | |
| CN1128999A (zh) | 杂环化合物 | |
| US7345190B2 (en) | Carnitine conjugates as dual prodrugs and uses thereof | |
| WO2012129942A1 (zh) | 手性3-羟基吡啶-4-酮类衍生物及其合成和用途 | |
| JP2018507880A5 (https=) | ||
| JP7194817B2 (ja) | トレプロスチニルのエルブミン塩 | |
| AU2013200226B2 (en) | Compounds and method for reducing uric acid | |
| US8859824B2 (en) | Dual cation dual anion coordination complexes | |
| RU2021132455A (ru) | Новые твердые формы (2s,3s,4s,5r,6s)-3,4,5-тригидрокси-6-(((4ar,10ar)-7-гидрокси-1-пропил-1,2,3,4,4a,5,10,10a-октагидробензо[g]хинолин-6-ил)окси)тетрагидро-2h-пиран-2-карбоновой кислоты | |
| HK40092836A (zh) | 用於预防或减轻对用於帕金森病、特别是l-dopa诱导的运动障碍的药学药物的致敏的[2-(3-氟-5-甲磺酰基苯氧基)乙基](丙基)胺(美多培坦) | |
| AU2025200217A1 (en) | Systems and methods for preparing tailored radioactive isotope solutions | |
| JPWO2021152201A5 (https=) | ||
| WO2010145800A1 (en) | Salts of tramadol and diflunisal and their crystal form in the treatment of pain | |
| BRPI0708586A2 (pt) | derivados heterocìclicos cicloalquilas, respectivo processo de preparo e composições farmacêuticas que contêm |